inveox

About inveox GmbH |

Founded in Munich in 2017, inveox develops systems to digitize, automate and connect histopathology laboratories and physicians. The aim is to increase the safety and reliability of cancer diagnoses, while at the same time improving the efficiency and profitability of laboratories and tapping the potential for personalized diagnostics based on big data and AI.

Having won numerous awards, inveox was a finalist for the 2020 Digital Startup of the Year Award by Germany’s Federal Ministry of Economics, the 2019 EIT Woman Award and the 2018 World Health Summit Award. Inveox also made it onto the 2018 Forbes list of “most promising startups” and has been covered by large media outlets such as Handelsblatt and Wirtschaftswoche. The medtech company has also been a member of the World Economic Forum since 2019.

In response to the COVID-19 pandemic, inveox launched a second line of business in 2020 providing medical supplies to healthcare institutions worldwide. With subsidiaries in Krakow, Poland, and Houston, Texas, USA, the young company currently comprises of over 100 team members in all offices.

For more information about inveox, visit inveox.com.

inveox has the goal of making cancer diagnosis faster, safer, and more reliable. In today’s labs, tissue samples (biopsies) are at risk of being mixed-up, contaminated or lost. But our products are designed to work as a cohesive unit to make this a thing of the past. We help patients and doctors. In addition, we create the lab of the future by bringing big data, artificial intelligence, and machine learning to labs. This provides better research data for scientists so they can eradicate cancer.